Seo Min-Wook, Park Tae-Eun
Department of Biomedical Engineering, Ulsan National Institute of Science and Technology, Ulsan, 44919 South Korea.
Biomed Eng Lett. 2021 Jul 19;11(3):211-216. doi: 10.1007/s13534-021-00198-5. eCollection 2021 Aug.
A major challenge in treating neurogenerative diseases is delivering drugs across the blood-brain barrier (BBB). In this review, we summarized the development of liposome-based drug delivery system with enhanced BBB penetration for efficient brain drug delivery. We focused on the liposome-based therapeutics targeting Alzheimer's disease and Parkinson's disease because they are most common types of adult chronic neurodegenerative disorders. A variety of liposome with surface modification of BBB-targeting ligands have been created to cross the BBB via transcytosis to the therapeutic efficacy of Alzheimer's disease and Parkinson's disease drugs. Recent advances in liposome are providing alternatives to overcome BBB for more efficient therapeutic strategy. To improve the BBB penetration of liposomes, we need to completely understand the pathophysiological changes at the BBB.
治疗神经退行性疾病的一个主要挑战是使药物穿越血脑屏障(BBB)。在本综述中,我们总结了具有增强血脑屏障穿透能力的基于脂质体的药物递送系统的发展,以实现高效的脑内药物递送。我们重点关注针对阿尔茨海默病和帕金森病的基于脂质体的疗法,因为它们是成人慢性神经退行性疾病中最常见的类型。已经制备了多种经血脑屏障靶向配体表面修饰的脂质体,以通过转胞吞作用穿越血脑屏障,从而提高阿尔茨海默病和帕金森病药物的治疗效果。脂质体的最新进展为克服血脑屏障提供了替代方案,以实现更有效的治疗策略。为了提高脂质体对血脑屏障的穿透能力,我们需要全面了解血脑屏障处的病理生理变化。